Weekly Analysts’ Ratings Changes for Biomea Fusion (BMEA)

A number of firms have modified their ratings and price targets on shares of Biomea Fusion (NASDAQ: BMEA) recently:

• 4/2/2025 – Biomea Fusion had its price target lowered by analysts at Barclays PLC from $11.00 to $3.00. They now have an “equal weight” rating on the stock.
• 3/31/2025 – Biomea Fusion had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 3/24/2025 – Biomea Fusion was given a new $10.00 price target on by analysts at Oppenheimer Holdings Inc..
• 3/24/2025 – Biomea Fusion had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
• 3/19/2025 – Biomea Fusion had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.

Biomea Fusion Stock Up 8.5 %

Biomea Fusion stock traded up $0.17 during mid-day trading on Wednesday, hitting $2.16. 913,747 shares of the company were exchanged, compared to its average volume of 916,666. The business has a fifty day moving average of $3.24 and a 200 day moving average of $5.92. Biomea Fusion, Inc. has a 1-year low of $1.92 and a 1-year high of $14.43. The company has a market capitalization of $78.28 million, a PE ratio of -0.54 and a beta of -0.26.

Biomea Fusion (NASDAQ:BMEA) last issued its earnings results on Monday, March 31st. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.19. Research analysts expect that Biomea Fusion, Inc. will post -3.93 earnings per share for the current year.

Institutional Investors Weigh In On Biomea Fusion

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. raised its position in shares of Biomea Fusion by 14.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 24,005 shares of the company’s stock valued at $93,000 after purchasing an additional 3,005 shares during the period. Wexford Capital LP boosted its holdings in Biomea Fusion by 2.3% in the fourth quarter. Wexford Capital LP now owns 133,343 shares of the company’s stock valued at $517,000 after acquiring an additional 3,007 shares during the last quarter. Geode Capital Management LLC grew its stake in Biomea Fusion by 0.7% during the third quarter. Geode Capital Management LLC now owns 601,479 shares of the company’s stock worth $6,076,000 after purchasing an additional 4,291 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Biomea Fusion by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 12,914 shares of the company’s stock valued at $50,000 after purchasing an additional 4,399 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of Biomea Fusion by 27.6% during the fourth quarter. JPMorgan Chase & Co. now owns 22,535 shares of the company’s stock worth $87,000 after purchasing an additional 4,868 shares during the period. 96.72% of the stock is currently owned by institutional investors and hedge funds.

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.